Please login to the form below

Not currently logged in
Email:
Password:

hepatitis C

This page shows the latest hepatitis C news and features for those working in and with pharma, biotech and healthcare.

Long-serving R&D head Bischofberger to leave Gilead

Long-serving R&D head Bischofberger to leave Gilead

During his tenure he oversaw the launch of a raft of HIV and hepatitis C and B therapies. ... McHutchison has been at Gilead since 2010, joining the company from Duke University Medical Center, and has been a key figure in the company hepatitis

Latest news

More from news
Approximately 104 fully matching, plus 268 partially matching documents found.

Latest Intelligence

  • IQVIA: The High IQ Approach of Human Data Science IQVIA: The High IQ Approach of Human Data Science

    Therapeutic advances during that same period have been remarkable; who would have thought we’d find a cure for hepatitis C, or see immunotherapy transform outcomes in cancer care?

  • Pharma deals continue to slide Pharma deals continue to slide

    On the other hand, Gilead has been under pressure from investors to do something with its $36.6bn cash, especially as its sales, largely driven by hepatitis C products, fell by

  • When science is not enough When science is not enough

    Witness Gilead’s hepatitis C drug sovaldi (sofosbuvir) which has glowing efficacy results yet is having a troubled transition into the market place.

  • Driving effective NICE implementation Driving effective NICE implementation

    Of course, for some disease areas the traditional health economic data has more resonance than for others - for example in high-cost therapy areas such as oncology, hepatitis C and many

  • Cost containment and the German market Cost containment and the German market

    This enormous boost is due to the modern hepatitis C treatment which also explains the decline in the market of immune stimulants and interferons by 12%, since interferons are no longer ... The majority of these new products are expensive and are

More from intelligence
Approximately 3 fully matching, plus 29 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics